Advertisement

Breast Cancer Research and Treatment

, Volume 39, Issue 2, pp 221–233 | Cite as

Cathepsins D, B, and L in transformed human breast epithelial cells

  • Tamara T. Lah
  • Gloria Calaf
  • Endre Kalman
  • Balasahib G. Shinde
  • Robert Somers
  • Sandino Estrada
  • Enrique Salero
  • Jose Russo
  • Ierachmiel Daskal
Report

Abstract

To investigate the regulation of lysosomal enzymes during carcinogenesis, we measured cathepsins (Cats) D, B, and L in MCF-10F, which is a human breast epithelial cell line, and cells evolved after treatment with carcinogen and transfected with c-Ha-ras oncogene. The clones used in this study, MCF-10FTras, D3, D3-1, and D3-1Tras, expressed no estrogen receptors and gradually increased invasive potential, while oncogenetransfected lines were also tumorigenic in SCID mice [16,19]. Cats D, B, and L were determined in the cells and in cell media using enzyme-linked immunosorbent assay (ELISA), specific enzyme activity measurements, and immunocytochemistry. The major intra- and extracellular lysosomal proteinase in these cells was Cat D (30–180 pm/mg), followed by Cat B (2–10 pm/mg) and Cat L (1–5 pm/mg). An inverse relationship between intracellular Cat D levels and invasive potential of carcinogen-treated and c-Ha-ras oncogene-transfected cell lines was observed. No significant changes in extracellular concentration of Cat D precursor in this series of cell lines was observed. Intracellular levels of Cats B and L were unchanged or slightly lower in carcinogentreated D3 and D3-1 cells, as well as in MCF-10FTras. On the other hand, in D3-1Tras cell line, evolving from c-Ha-ras transfected D3-1 line, 3.5 fold and 4.4 fold increases in Cat B and Cat L, respectively, but a 2 fold decrease in Cat D, were observed compared to the parental cell line. Immunocytochemical staining showed a granular, polarized perinuclear and cytoplasmic staining of cathepsins in all cell lines. Cysteine proteinases stained more frequently and more intensely in D3-1Tras compared to other lines, confirming the immunochemical assays. We hypothesize that several molecular events, caused by a carcinogen and an oncogene such as c-Ha-ras, are needed to increase Cat B and Cat L, but not Cat D, expression. Therefore, the cysteine and aspartic lysosomal proteinases are differentially expressed in the breast cell lines with more invasive phenotype.

Key words

breast cancer carcinogens cathepsin D cathepsin B cathepsin L c-Ha-ras oncogene invasion tumorigenicity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sloane BF, Moin K, Lah TT: Lysosomal enzymes and their endogenous inhibitors in neoplasia. In: Pretlow TG, Pretlow TH (eds): Biochemical and Molecular Aspects of Selected Cancers. Acad. Press, New York, 1993 vol 2: pp 411–466Google Scholar
  2. 2.
    Lah TT, Kokalj-Kunovar M, Štrukelj B, Pungerčar J, Maganja D-B, Drobnič-Koškorok M, Kastelic L, Babnik J, Golouh R, Turk V: Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 50: 36–44, 1992PubMedGoogle Scholar
  3. 3.
    Gabrijelčič D, Svetic B, Spaič D, Šrk J, Budihna M, Dolenec I, Popovič T, Cotič V, Turk V: Cathepsins B, H and L in human breast. Europ J Clin Chem Biochem 30: 69–74, 1992Google Scholar
  4. 4.
    Rochefort H, Capony F, Garcia M: Cathepsin D: A protease involved in breast cancer metastasis. Cancer and Metastasis Reviews 9: 321–331, 1990PubMedGoogle Scholar
  5. 5.
    Ravdin PM: Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Research and Treatment 24: 219–226, 1993PubMedGoogle Scholar
  6. 6.
    Garcia M, Deroq D, Pujol P, Rochefort H: Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5: 1809–1814, 1990PubMedGoogle Scholar
  7. 7.
    Capony F, Rougeot C, Cavailles V, Rochefort H: Estradiol increases the secretion by MCF7 cells of several lysosomal pro-enzymes. Biochem Biophys Res Commun 171: 972–987, 1990PubMedGoogle Scholar
  8. 8.
    Mort JS, Recklies AD: Interrelationship of active and latent secreted human cathepsin B precursors. Biochem J 233: 57–63, 1986PubMedGoogle Scholar
  9. 9.
    Krepela E, Bartek J, Skalkova D, Vicar J, Rasnick D, Taylor-Papadimitriou J, Hallowes RC: Cytochemical and biochemical evidence of cathepsin B in malignant, transformed and normal breast epithelial cells. J Cell Science 87: 145–154, 1987PubMedGoogle Scholar
  10. 10.
    Chuahan SS, Goldstein LJ, Gottesman MM: Expression of cathepsin L in human tumors. Cancer Res 50: 1478–1480, 1990Google Scholar
  11. 11.
    Kane SS, Gottesman MM: The role of cathepsin L in malignant transformation. Seminars in Cancer Biology 1: 127–136, 1990PubMedGoogle Scholar
  12. 12.
    Chambers AF, Collela R, Denhardt DT, Wilson SM: Increased expression of cathepsins L and B, and decreased activity of their inhibitors, in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinogenesis 5: 238–245, 1992Google Scholar
  13. 13.
    Chambers AF, Tuck AB: Ras-responsive genes and tumor metastasis. Critical Reviews in Oncogenesis 4: 95–114, 1993PubMedGoogle Scholar
  14. 14.
    Zhang J-Y, Schultz RM: Fibroblasts transformed by different ras oncogenes show dissimilar patterns of protease gene expression and regulation. Cancer Res 52: 6682–6689, 1992PubMedGoogle Scholar
  15. 15.
    Sloane BF, Rozhin J, Moin K, Ziegler G, Fong D, Muschel RJ: Cysteine endopeptidases and their inhibitors in malignant progression of rat embryo fibroblasts. Biol Chem Hoppe-Seyler 373: 589–594, 1992PubMedGoogle Scholar
  16. 16.
    Calaf G, Russo J: Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 14: 483–492, 1993PubMedGoogle Scholar
  17. 17.
    Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, MacGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6078–6094, 1990Google Scholar
  18. 18.
    Basolo F, Elliott J, Tait L, Chen XQ, Maloney T, Russo IH, Pauley R, Momiki S, Caamano J, Klein-Szanto AJP, Koszalka M, Russo J: Transformation in human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinogenesis 4: 25–35, 1991Google Scholar
  19. 19.
    Calaf G, Tahin Q, Alvarado ME, Estrada S, Cox T, Russo J: Hormone receptors and cathepsin D levels in human breast epithelial cells transformed by chemical carcinogens and c-Ha-ras transfection. Breast Cancer Res and Treatment 29: 169–177, 1993Google Scholar
  20. 20.
    Calaf G, Estrada S, Zhang P-L, Alvarado ME, Russo J: c-Ha-ras oncogene enhances the tumorigenic phenotype of human breast epithelial cells transformed with a chemical carcinogenin vitro. Proc Am Assoc Cancer Res 34: 120, 1993Google Scholar
  21. 21.
    Bradford M: A rapid, sensitive method for the quantitation of µg quantities of protein, utilizing the principle of proteindye binding. Anal Biochem 72: 248–254, 1976PubMedGoogle Scholar
  22. 22.
    Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H:In vitro degradation of extracellular matrix. Cancer Res 48: 3688–3692, 1988PubMedGoogle Scholar
  23. 23.
    Mason RW, Green GDJ, Barrett AJ: Human liver cathepsin L. Biochem J 226: 233–241, 1986Google Scholar
  24. 24.
    Russo J, Russo IH, Calaf G, Zhang P-L, Barnabas N: Breast susceptibility to carcinogenesis. In: Nandi S, Li J. (eds). Hormonal Carcinogenesis, Springer Verlag Berlin, 1995 (in press)Google Scholar
  25. 25.
    Lah T, Calaf G, Kalman E, Shinde B, Somers R, Estrada S, Salero E, Russo J, Daskal I: Cathepsins B and L, but not cathepsin D, are related to the progression of human breast epithelial cells (HBEC) transformation abstract980I. Proc Am Assoc Cancer Res 35: 164, 1994Google Scholar
  26. 26.
    Lah TT, Calaf G, Kalman E, Russo J, Jarosz D, Zabrecky J, Somers R and Daskal I: Cathepsins D, B, and L in breast carcinoma and in transformed human breast epithelial cell (HBEC). Biol Chem Hoppe Seyler 376: 357–376, 1995PubMedGoogle Scholar
  27. 27.
    Johnson MD, Torri JA, Lippman ME, Dickson RB: The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 53: 7873–7877, 1993Google Scholar
  28. 28.
    Gabel CA, Goldberg DE, Kornfeld S: Identification and characterization of cells deficient of the mannose-6-phosphate receptor: evidence for an alternative pathway for lysosomal enzyme targeting. Proc Natl Acad Sci USA 80: 775–781, 1983PubMedGoogle Scholar
  29. 29.
    Brouillet JP, Spyratos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelonde T, Rochefort H: Immunoradiometric assay of pro-cathepsin D in breast cancer cytosols relative prognostic value versus total cathepsin D. Europ J Cancer 29A: 9: 1248–1251, 1993Google Scholar
  30. 30.
    Zhang P-L, Calaf G, Russo H: Allele loss and point mutation in codons 12 and 61 of the c-Ha-ras oncogene in carcinogen-transformed human breast epithelial cells. Molecular Carcinogenesis 9: 46–56, 1994PubMedGoogle Scholar
  31. 31.
    Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J, Ziegler G: Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Science 107: 373–384, 1994PubMedGoogle Scholar
  32. 32.
    Sloane BF, Sameni M, Cao L, Berquin I, Rozhin J, Ziegler G, Moin K, Day N: Alterations in processing and trafficking of cathepsin B during malignant progression. In: Katunuma N, Suzuki K, Travis J, Fritz H (eds) Biological Functions of Proteases and Inhibitors. Japan Sci Soc Press Tokyo, 1993 pp 131–147, 1993Google Scholar
  33. 33.
    Lah TT, Kokalj-Kunovar M, Drobnič-Košorok M, Babnik J, Golouh R, Vrhovec I, Turk V: Stefins and cathepsins in breast carcinoma. Biol Chem Hoppe-Seyler, Suppl 371: 434–438, 1992Google Scholar
  34. 34.
    Kolar Z, Järvinen M, Negrini R: Demonstration of proteinase inhibitors cystatin A, B and C in breast cancer and in cell lines MCF-7 and ZR-75-1. Neoplasma 36: 185–189, 1989PubMedGoogle Scholar
  35. 35.
    Hamilton RT, Bruns KA, Delgado ME, Shim JK, Fang Y, Denhardt DT, Hamilton MN: Developmental expression of cathepsin L and c-Ha-ras in the mouse placenta. Mol Reproduction and Development 30: 285–291, 1991Google Scholar
  36. 36.
    Mason RW, Wilcox D, Wikstrom P, Shaw E: The identification of active forms of cysteine proteinases in Kirsten-virus transformed mouse fibroblasts by use of a specific radiolabelled inhibitor. Biochem J 248: 449–454, 1989Google Scholar
  37. 37.
    Gal S, Gottesman MM: The major excreted protein of transformed fibroblasts is an acid activatable protease. J Biol Chem 262: 1760–1765, 1986Google Scholar
  38. 38.
    Lee HK, Jones RT, Myers R, Marzella L: Regulation of protein degradation in normal and transformed human bronchial epithelial cells in culture. Arch Biochem Biophys 296: 271–278, 1992PubMedGoogle Scholar
  39. 39.
    Gunn JM, James G: Protein turnover in 3T3 cells transformed with the oncogene c-H-ras1. Biochem J 283: 427–433, 1992PubMedGoogle Scholar
  40. 40.
    Russo J, Russo IH: Biology of disease: Biological and molecular bases of mammary carcinogenesis. Laboratory Invest 57: 112–137, 1987Google Scholar
  41. 41.
    Lah TT, Vrhovec I, Golouh R, Babnik J, Turk V, Tabachnick I, Daskal I: Lysosomal proteinases in malignant breast carcinoma. Clinical and Exp Metastasis 10: Suppl 1, p 72, 1992Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Tamara T. Lah
    • 1
  • Gloria Calaf
    • 3
  • Endre Kalman
    • 1
  • Balasahib G. Shinde
    • 1
  • Robert Somers
    • 2
  • Sandino Estrada
    • 3
  • Enrique Salero
    • 3
  • Jose Russo
    • 3
  • Ierachmiel Daskal
    • 1
  1. 1.Department of Pathology and Laboratory MedicineAlbert Einstein Medical CenterPhiladelphiaUSA
  2. 2.Department of SurgeryAlbert Einstein Medical CenterPhiladelphiaUSA
  3. 3.Department of PathologyFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations